TNP-470: an angiogenesis inhibitor in clinical development for cancer. - Wikidata - wikimedia - TriplyDB

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

http://www.wikidata.org/entity/Q34074922

about

Effect of nitroxoline on angiogenesis and growth of human bladder cancer An orally delivered small-molecule formulation with antiangiogenic and anticancer activity Pyridinylpyrimidines selectively inhibit human methionine aminopeptidase-1 Pyridinylquinazolines Selectively Inhibit Human Methionine Aminopeptidase-1 in Cells Phosphatase inhibitors with anti-angiogenic effect in vitro Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.Angiogenesis inhibitors: current strategies and future prospects.Adipose tissue mass can be regulated through the vasculature.Anti-angiogenic treatment strategies for the therapy of endometriosis.Mutations at the S1 sites of methionine aminopeptidases from Escherichia coli and Homo sapiens reveal the residues critical for substrate specificity.Exploring the role of mitochondrial UQCRB in angiogenesis using small molecules.Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest Cellular actions and signaling by endostatin.In vitro and in vivo evaluation of the anti-angiogenic actions of 4-hydroxybenzyl alcohol.Tumor angiogenesis as a target for dietary cancer prevention Disruption of Wnt planar cell polarity signaling by aberrant accumulation of the MetAP-2 substrate Rab37.Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay.Effects of TNP-470 on proliferation and apoptosis in human colon cancer xenografts in nude mice.Angiogenesis is required for stress fracture healing in rats.The fumagillin biosynthetic gene cluster in Aspergillus fumigatus encodes a cryptic terpene cyclase involved in the formation of β-trans-bergamotene Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.Mutation of H63 and its catalytic affect on the methionine aminopeptidase from Escherichia coli.Novel technologies for antiangiogenic drug delivery in the brain.Generation of complexity in fungal terpene biosynthesis: discovery of a multifunctional cytochrome P450 in the fumagillin pathway.Ariadne's ChemEffect and Pathway Studio knowledge base.Anticancer and antifungal compounds from Aspergillus, Penicillium and other filamentous fungi.Terpenoids from the Marine-Derived Fungus Aspergillus fumigatus YK-7.2,5-diketopiperazines from the marine-derived fungus Aspergillus fumigatus YK-7.Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target.NC2213: a novel methionine aminopeptidase 2 inhibitor in human colon cancer HT29 cells.Computational approaches for drug repositioning and combination therapy design.TNP-470 inhibits 7,12-dimethylbenz[a]anthracene-induced mammary tumor formation when administered before the formation of carcinoma in situ but is not additive with tamoxifen.Synthesis and SAR studies of praziquantel derivatives with activity against Schistosoma japonicum.Anti-angiogenic drug loaded liposomes: Nanotherapy for early atherosclerotic lesions in mice.Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells

P2860

Q24629326-F3BB2AFE-F286-4607-B171-6300ECFFCF4E Q24649290-66FD6123-CB07-4181-A964-FC315C9E310F Q27676869-7F11BB04-76CB-448E-AB13-B5F540C26114 Q27677949-5D016E35-77A8-45BB-B0C1-67FB610CB1B7 Q33588814-B0637842-D648-4552-9BC7-3FCD20B58533 Q33918981-2C1E0BF5-16D4-4EB0-9292-74563B118034 Q34056376-34ABCFA5-F147-4AD8-B9AA-62DFE83A5467 Q34075818-B11046FD-7B70-46EB-B2BC-957DA69FAE5F Q34283036-824BA234-F3C7-4B1A-AEF7-B2DFB46763DF Q34300043-87AF27B6-40A3-4788-9F00-AAC9F5048540 Q34332044-851F2867-5E6F-49D4-8CAD-4128DCD2049F Q34687606-7E54ED8F-EDB3-441F-80D6-DE399A1CD398 Q35008096-E6469BBF-12D7-4502-A33B-8623E50DE4AB Q35036197-B42A9FED-C27D-4DFE-80B1-620FB6EA2639 Q35250910-32F1CC2F-CDDB-49B0-B44A-C833ADAF8C39 Q35491403-CC274539-CB5A-4FCF-A837-5F09730CD090 Q35749086-699E29DD-7838-4E5E-8827-74D592134329 Q36178323-8E36304E-4D78-4AC3-B4E7-1C0C1BB3F428 Q36442977-3551119E-7768-488B-8C15-EB5C9C570916 Q36840486-786CB314-7242-4856-B0B9-669193A79CDA Q36890872-D5CD544E-77CE-4E0E-8427-B93F2165A8C8 Q36915728-CF086803-A4BF-46B8-AD64-AAF7A4327DE1 Q37117375-ADC3542A-DD58-4974-820A-2478E16084CB Q37172110-6633885D-F432-42F3-93AC-2715AEE34F3D Q37186246-88E9C5A8-B871-4E39-AA8E-599307F19E32 Q37701669-6223264C-6412-4C1F-B4DD-964150630146 Q38088349-E5D0BC7D-BF42-4F8F-89C4-ECE19FF01C9E Q38142539-82730F6B-43EB-486A-BD14-8F67A07BFBDB Q38806698-9C1C6F61-F9E6-4E7B-A44B-0B8CC8389F04 Q39394580-56DF57D9-2A21-4B32-AA79-B6BE17486CBB Q39571989-69ED01B2-FC62-4CA0-AF4E-D029591B54BF Q40142771-F0641B73-D012-4DF5-896B-56797ABC66AF Q42249201-1234DBC3-54CC-4F42-9279-E4B0FC4D37CF Q43015433-B76CD820-6161-4818-816A-E4516D0BA30A Q44513289-B11E8D98-0AD0-4DB0-A45A-E01DE95E902D Q46081944-1BA33112-48D7-468B-A167-655D86A43EDA Q48235332-A348E3FA-3D1A-4650-B89B-34E0316226FA Q57373805-06638FC0-1978-45B4-B50C-5F6A11D30DBD

P2860

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

http://www.wikidata.org/entity/Q34074922

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

name

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@ast

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@en

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@nl

type

label

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@ast

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@en

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@nl

prefLabel

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@ast

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@en

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@nl

P1433

Q34074922-3B24C2BE-934B-4A73-8A0C-4B8215349590

P1476

Q34074922-DA480FBF-352F-417B-BC5A-E3FE40436B6F

P2093

Q34074922-3ADB84D2-89F0-4DB7-9919-47EB78D049ED

Q34074922-EB568C78-8571-4DBC-9E81-424581BDB490

P2860

Q34074922-038345FD-5C95-40B9-B357-575E285B45C9

Q34074922-07F12C4D-DB38-48FC-A9C7-3B1F9F5AA05F

Q34074922-09EDB5BB-36DA-404D-ADBA-A4D33CA8767A

Q34074922-112622DC-9875-4ACB-AD94-14E3D330B363

Q34074922-1D75B113-612E-4FC6-ADFF-4EC592CFAA6E

Q34074922-215FE755-05DF-4DB8-8711-066F064E0922

Q34074922-2A80BA87-64F4-4F99-AB9F-51AD284C901A

Q34074922-2C3DF04F-E0DF-44E8-9095-8A649AB40938

Q34074922-2D2213A2-1F33-44FC-A86D-0DDF13F6B399

Q34074922-349C38FC-A34B-4E2F-AFFA-B13250A34A53

P304

Q34074922-72D3D915-7CC3-4E7B-8DDE-3CE43AB59A7D

P31

Q34074922-979B9F09-8B17-4255-B5D4-53008ED27B0B

P356

Q34074922-AAE4BAB7-9F63-4557-BF1A-32D311219888

P407

Q34074922-76A167EE-2933-49CF-B441-AA36C7A85273

P433

Q34074922-EED3B704-829A-4DFC-87F8-D50600A281FA

P478

Q34074922-B7DCCD18-A76C-4317-AA29-9099E1049F41

P577

Q34074922-60D478C0-59C2-43E5-8148-ACB61A881D10

P5875

Q34074922-467A12CB-726C-4133-B208-12D3C132E52A

P698

Q34074922-8F6D31AB-1A1E-47F4-B89C-2714C95FB0C3

P356

13543784.9.6.1383

P1433

Expert Opinion on Investigational Drugs

P1476

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

@en

P2093

E A Kruger

http://www.w3.org/2001/XMLSchema#string

W D Figg

http://www.w3.org/2001/XMLSchema#string

P2860

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Fibronectin controls capillary endothelial cell growth by modulating cell shape

The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats.

Inhibition of lymph node metastasis by an anti-angiogenic agent, TNP-470.

Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470

Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth

Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia.

P304

1383-1396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.9.6.1383

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2000-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12265674

http://www.w3.org/2001/XMLSchema#string

P698

11060750

http://www.w3.org/2001/XMLSchema#string